Last updated on May 2018
Denosumab Versus Bisphosphonates (Alendronate) in GIOP
Brief description of study
A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis
Detailed Study Description
Study design: an open-label randomized controlled trial Duration of study: 12 months
Treatment arms:
- Denosumab: a total of 2 doses in a period of 12 months
- Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients (110 patients in each arm)
Clinical Study Identifier: NCT03005678